Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Summary

The purpose of this study is to determine if Itacitinib in combination with erlotinib is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB/Stage IV or recurrent whose tumors have EGFR activating mutations.

Timeline

Start

2014-12

Primary completion

2015-09

Completion

2015-09

Outcome

Outcome not reported

Stopped (Enrollment): “Study withdrawn before enrolling first patient”

Drugs

Indications